Leukemia is classified according to the mode of presentation, i.e., acute or chronic, and the predominant proliferating cell type. Leukemias are a group of malignant neoplasms derived from the hematopoietic stem cells as a result of abnormal proliferation of blood cells in the bone marrow 1. In conclusion we found that Intravitreal MTX injections may be an effective therapeutic approach for eyes with intraocular leukemic tumor cell infiltration. All treated eyes showed improvement in the inflammatory reaction and tumor cell infiltration. The mean number of MTX injections was 3.37 ± 5.35 (range 1–18). The indication for treatment was biopsy proven, tumor cell infiltration. Eleven eyes of 6 patients were treated with intravitreal MTX injections. The 12 patients included 7 women and 5 men (mean age ± standard deviation at diagnosis 25.92 ± 23.91 years, range 2–82 years). Details on ocular inflammatory reaction and tumor cell infiltration at presentation and the end of follow-up were recorded as main outcome measures. The medical records of 12 consecutive patients with ocular leukemia (24 eyes, 11 eyes treated with MTX) treated at the Sheba Medical Center from January 2010 to December 2017 were retrospectively reviewed. We report, to the best of our knowledge for the first time, the ocular manifestation of a series of patients with ocular leukemia and the result of their treatment with intravitreal methotrexate (MTX) injections. Ocular symptoms can be the presenting signs of leukemia, they can appear after diagnosis has been established, or they can be the first manifestation of a relapse after remission. Ocular involvement in leukemia is considered rare.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |